EyePoint EYPT
NASDAQ EYPT
$4.58 +0.01 (+0.33%)
As of: Sep 4, 2026 · 3:59 PM EDT

EyePoint (EYPT) Depreciation & Amortization (CF) (2024 - 2026)

EyePoint (EYPT) posted Depreciation & Amortization (CF) of $636000.0 for Q1 2026, up 30.06% sequentially from $489000.0 in Q4 2025, and up 27.97% YoY from $497000.0 in Q1 2025.

Analysis

EyePoint (EYPT) Depreciation & Amortization (CF) (2024 - 2026) Analysis & Trends

EyePoint has reported Depreciation & Amortization (CF) for 17 years, with the latest figure at $636000.0 in Q1 2026.

  • Quarterly Depreciation & Amortization (CF) rose 27.97% year-over-year to $636000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (up 29.12% YoY) and the FY2025 annual result came in at $2.3 million, up 49.94% from the prior year.
  • Depreciation & Amortization (CF) grew to $636000.0 in Q1 2026 per EYPT's latest filing, from $489000.0 in the prior quarter.
  • Over five years, Depreciation & Amortization (CF) peaked at $636000.0 in Q1 2026 and troughed at $81000.0 in Q1 2022.
  • A 5-year average of $302117.6 and a median of $303000.0 in 2024 frame the typical range for Depreciation & Amortization (CF).
  • The sharpest annual moves came in 2023 and 2024: Depreciation & Amortization (CF) dropped 13.85% in 2023, then jumped 316.96% in 2024.
  • Over 5 years, Depreciation & Amortization (CF) stood at $130000.0 in 2022, then slipped by 13.85% to $112000.0 in 2023, then soared by 316.96% to $467000.0 in 2024, then gained by 4.71% to $489000.0 in 2025, then surged by 30.06% to $636000.0 in 2026.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $636000.0, $489000.0, and $576000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Depreciation & Amortization (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 56.50 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 123.70 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 40.52 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -
8 Royalty Pharma 28.45 Bn 27.61 Bn - -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn -
10 EyePoint 398.53 Mn 218.06 Mn 507,000.00 690,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 690,000.00
Mar 31, 2026 636,000.00
Jun 30, 2025 538,000.00
Mar 31, 2025 497,000.00
Dec 31, 2024 467,000.00